Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT

Background/Objectives: Our objective was to investigate effects of an oral nutritional supplement containing n-3 polyunsaturated fatty acids (FAs) on quality of life, performance status, handgrip strength and physical activity in patients with non-small cell lung cancer (NSCLC) undergoing multimodal...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of clinical nutrition Vol. 66; no. 3; pp. 399 - 404
Main Authors van der Meij, B S, Langius, J A E, Spreeuwenberg, M D, Slootmaker, S M, Paul, M A, Smit, E F, van Leeuwen, P A M
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.03.2012
Nature Publishing Group
Subjects
Online AccessGet full text
ISSN0954-3007
1476-5640
1476-5640
DOI10.1038/ejcn.2011.214

Cover

Loading…
Abstract Background/Objectives: Our objective was to investigate effects of an oral nutritional supplement containing n-3 polyunsaturated fatty acids (FAs) on quality of life, performance status, handgrip strength and physical activity in patients with non-small cell lung cancer (NSCLC) undergoing multimodality treatment. Subjects/Methods: In a double-blind experiment, 40 patients with stage III NSCLC were randomised to receive 2 cans/day of a protein- and energy-dense oral nutritional supplement containing n-3 polyunsaturated FAs (2.02 g eicosapentaenoic acid+0.92 g docosahexaenoic acid/day) or an isocaloric control supplement, during multimodality treatment. Quality of life, Karnofsky Performance Status, handgrip strength and physical activity (by wearing an accelerometer) were assessed. Effects of intervention were analysed by generalised estimating equations. P -values <0.05 were regarded as statistically significant. Results: The intervention group reported significantly higher on the quality of life parameters, physical and cognitive function (B=11.6 and B=20.7, P <0.01), global health status (B=12.2, P =0.04) and social function (B=22.1, P =0.04) than the control group after 5 weeks. The intervention group showed a higher Karnofsky Performance Status (B=5.3, P =0.04) than the control group after 3 weeks. Handgrip strength did not significantly differ between groups over time. The intervention group tended to have a higher physical activity than the control group after 3 and 5 weeks (B=6.6, P =0.04 and B=2.5, P =0.05). Conclusion: n-3 Polyunsaturated FAs may beneficially affect quality of life, performance status and physical activity in patients with NSCLC undergoing multimodality treatment.
AbstractList BACKGROUND/OBJECTIVES: Our objective was to investigate effects of an oral nutritional supplement containing n-3 polyunsaturated fatty acids (FAs) on quality of life, performance status, handgrip strength and physical activity in patients with non-small cell lung cancer (NSCLC) undergoing multimodality treatment. SUBJECTS/METHODS: In a double-blind experiment, 40 patients with stage III NSCLC were randomised to receive 2 cans/day of a protein-and energy-dense oral nutritional supplement containing n-3 polyunsaturated FAs (2.02 g eicosapentaenoic acid + 0.92 g docosahexaenoic acid/day) or an isocaloric control supplement, during multimodality treatment. Quality of life, Karnofsky Performance Status, handgrip strength and physical activity (by wearing an accelerometer) were assessed. Effects of intervention were analysed by generalised estimating equations. P-values <0.05 were regarded as statistically significant. RESULTS: The intervention group reported significantly higher on the quality of life parameters, physical and cognitive function (B = 11.6 and B = 20.7, P<0.01), global health status (B = 12.2, P = 0.04) and social function (B = 22.1, P = 0.04) than the control group after 5 weeks. The intervention group showed a higher Karnofsky Performance Status (B = 5.3, P = 0.04) than the control group after 3 weeks. Handgrip strength did not significantly differ between groups over time. The intervention group tended to have a higher physical activity than the control group after 3 and 5 weeks (B = 6.6, P = 0.04 and B = 2.5, P = 0.05). CONCLUSION: n-3 Polyunsaturated FAs may beneficially affect quality of life, performance status and physical activity in patients with NSCLC undergoing multimodality treatment. European Journal of Clinical Nutrition (2012) 66, 399-404; doi: 10.1038/ejcn.2011.214; published online 11 January 2012 Keywords: n-3 fatty acids; eicosapenaenoic acid; lung neoplasms; quality of life; RCT
Our objective was to investigate effects of an oral nutritional supplement containing n-3 polyunsaturated fatty acids (FAs) on quality of life, performance status, handgrip strength and physical activity in patients with non-small cell lung cancer (NSCLC) undergoing multimodality treatment.BACKGROUND/OBJECTIVESOur objective was to investigate effects of an oral nutritional supplement containing n-3 polyunsaturated fatty acids (FAs) on quality of life, performance status, handgrip strength and physical activity in patients with non-small cell lung cancer (NSCLC) undergoing multimodality treatment.In a double-blind experiment, 40 patients with stage III NSCLC were randomised to receive 2 cans/day of a protein- and energy-dense oral nutritional supplement containing n-3 polyunsaturated FAs (2.02 g eicosapentaenoic acid+0.92 g docosahexaenoic acid/day) or an isocaloric control supplement, during multimodality treatment. Quality of life, Karnofsky Performance Status, handgrip strength and physical activity (by wearing an accelerometer) were assessed. Effects of intervention were analysed by generalised estimating equations. P-values <0.05 were regarded as statistically significant.SUBJECTS/METHODSIn a double-blind experiment, 40 patients with stage III NSCLC were randomised to receive 2 cans/day of a protein- and energy-dense oral nutritional supplement containing n-3 polyunsaturated FAs (2.02 g eicosapentaenoic acid+0.92 g docosahexaenoic acid/day) or an isocaloric control supplement, during multimodality treatment. Quality of life, Karnofsky Performance Status, handgrip strength and physical activity (by wearing an accelerometer) were assessed. Effects of intervention were analysed by generalised estimating equations. P-values <0.05 were regarded as statistically significant.The intervention group reported significantly higher on the quality of life parameters, physical and cognitive function (B=11.6 and B=20.7, P<0.01), global health status (B=12.2, P=0.04) and social function (B=22.1, P=0.04) than the control group after 5 weeks. The intervention group showed a higher Karnofsky Performance Status (B=5.3, P=0.04) than the control group after 3 weeks. Handgrip strength did not significantly differ between groups over time. The intervention group tended to have a higher physical activity than the control group after 3 and 5 weeks (B=6.6, P=0.04 and B=2.5, P=0.05).RESULTSThe intervention group reported significantly higher on the quality of life parameters, physical and cognitive function (B=11.6 and B=20.7, P<0.01), global health status (B=12.2, P=0.04) and social function (B=22.1, P=0.04) than the control group after 5 weeks. The intervention group showed a higher Karnofsky Performance Status (B=5.3, P=0.04) than the control group after 3 weeks. Handgrip strength did not significantly differ between groups over time. The intervention group tended to have a higher physical activity than the control group after 3 and 5 weeks (B=6.6, P=0.04 and B=2.5, P=0.05).n-3 Polyunsaturated FAs may beneficially affect quality of life, performance status and physical activity in patients with NSCLC undergoing multimodality treatment.CONCLUSIONn-3 Polyunsaturated FAs may beneficially affect quality of life, performance status and physical activity in patients with NSCLC undergoing multimodality treatment.
Background/Objectives: Our objective was to investigate effects of an oral nutritional supplement containing n-3 polyunsaturated fatty acids (FAs) on quality of life, performance status, handgrip strength and physical activity in patients with non-small cell lung cancer (NSCLC) undergoing multimodality treatment. Subjects/Methods: In a double-blind experiment, 40 patients with stage III NSCLC were randomized to receive 2 cans/day of a protein- and energy-dense oral nutritional supplement containing n-3 polyunsaturated FAs (2.02g eicosapentaenoic acid+0.92g docosahexaenoic acid/day) or an isocaloric control supplement, during multimodality treatment. Quality of life, Karnofsky Performance Status, handgrip strength and physical activity (by wearing an accelerometer) were assessed. Effects of intervention were analyzed by generalized estimating equations. P-values <0.05 were regarded as statistically significant. Results: The intervention group reported significantly higher on the quality of life parameters, physical and cognitive function (B=11.6 and B=20.7, P<0.01), global health status (B=12.2, P=0.04) and social function (B=22.1, P=0.04) than the control group after 5 weeks. The intervention group showed a higher Karnofsky Performance Status (B=5.3, P=0.04) than the control group after 3 weeks. Handgrip strength did not significantly differ between groups over time. The intervention group tended to have a higher physical activity than the control group after 3 and 5 weeks (B=6.6, P=0.04 and B=2.5, P=0.05). Conclusion: n-3 Polyunsaturated FAs may beneficially affect quality of life, performance status and physical activity in patients with NSCLC undergoing multimodality treatment.[PUBLICATION ABSTRACT]
Background/Objectives: Our objective was to investigate effects of an oral nutritional supplement containing n-3 polyunsaturated fatty acids (FAs) on quality of life, performance status, handgrip strength and physical activity in patients with non-small cell lung cancer (NSCLC) undergoing multimodality treatment. Subjects/Methods: In a double-blind experiment, 40 patients with stage III NSCLC were randomised to receive 2 cans/day of a protein- and energy-dense oral nutritional supplement containing n-3 polyunsaturated FAs (2.02 g eicosapentaenoic acid+0.92 g docosahexaenoic acid/day) or an isocaloric control supplement, during multimodality treatment. Quality of life, Karnofsky Performance Status, handgrip strength and physical activity (by wearing an accelerometer) were assessed. Effects of intervention were analysed by generalised estimating equations. P -values <0.05 were regarded as statistically significant. Results: The intervention group reported significantly higher on the quality of life parameters, physical and cognitive function (B=11.6 and B=20.7, P <0.01), global health status (B=12.2, P =0.04) and social function (B=22.1, P =0.04) than the control group after 5 weeks. The intervention group showed a higher Karnofsky Performance Status (B=5.3, P =0.04) than the control group after 3 weeks. Handgrip strength did not significantly differ between groups over time. The intervention group tended to have a higher physical activity than the control group after 3 and 5 weeks (B=6.6, P =0.04 and B=2.5, P =0.05). Conclusion: n-3 Polyunsaturated FAs may beneficially affect quality of life, performance status and physical activity in patients with NSCLC undergoing multimodality treatment.
SUBJECTS/METHODS: In a double-blind experiment, 40 patients with stage III NSCLC were randomised to receive 2 cans/day of a protein-and energy-dense oral nutritional supplement containing n-3 polyunsaturated FAs (2.02 g eicosapentaenoic acid + 0.92 g docosahexaenoic acid/day) or an isocaloric control supplement, during multimodality treatment. Quality of life, Karnofsky Performance Status, handgrip strength and physical activity (by wearing an accelerometer) were assessed. Effects of intervention were analysed by generalised estimating equations. P-values <0.05 were regarded as statistically significant. European Journal of Clinical Nutrition (2012) 66, 399-404; doi: 10.1038/ejcn.2011.214; published online 11 January 2012
Our objective was to investigate effects of an oral nutritional supplement containing n-3 polyunsaturated fatty acids (FAs) on quality of life, performance status, handgrip strength and physical activity in patients with non-small cell lung cancer (NSCLC) undergoing multimodality treatment. In a double-blind experiment, 40 patients with stage III NSCLC were randomised to receive 2 cans/day of a protein- and energy-dense oral nutritional supplement containing n-3 polyunsaturated FAs (2.02 g eicosapentaenoic acid+0.92 g docosahexaenoic acid/day) or an isocaloric control supplement, during multimodality treatment. Quality of life, Karnofsky Performance Status, handgrip strength and physical activity (by wearing an accelerometer) were assessed. Effects of intervention were analysed by generalised estimating equations. P-values <0.05 were regarded as statistically significant. The intervention group reported significantly higher on the quality of life parameters, physical and cognitive function (B=11.6 and B=20.7, P<0.01), global health status (B=12.2, P=0.04) and social function (B=22.1, P=0.04) than the control group after 5 weeks. The intervention group showed a higher Karnofsky Performance Status (B=5.3, P=0.04) than the control group after 3 weeks. Handgrip strength did not significantly differ between groups over time. The intervention group tended to have a higher physical activity than the control group after 3 and 5 weeks (B=6.6, P=0.04 and B=2.5, P=0.05). n-3 Polyunsaturated FAs may beneficially affect quality of life, performance status and physical activity in patients with NSCLC undergoing multimodality treatment.
Audience Professional
Academic
Author Langius, J A E
Spreeuwenberg, M D
van Leeuwen, P A M
Slootmaker, S M
Paul, M A
van der Meij, B S
Smit, E F
Author_xml – sequence: 1
  givenname: B S
  surname: van der Meij
  fullname: van der Meij, B S
  organization: Department of Nutrition and Dietetics, Internal Medicine, VU University Medical Center Amsterdam
– sequence: 2
  givenname: J A E
  surname: Langius
  fullname: Langius, J A E
  organization: Department of Nutrition and Dietetics, Internal Medicine, VU University Medical Center Amsterdam
– sequence: 3
  givenname: M D
  surname: Spreeuwenberg
  fullname: Spreeuwenberg, M D
  organization: Department of Epidemiology and Biostatistics, VU University Medical Center Amsterdam
– sequence: 4
  givenname: S M
  surname: Slootmaker
  fullname: Slootmaker, S M
  organization: Department of Public and Occupational Health, EMGO Institute, VU University Medical Center Amsterdam
– sequence: 5
  givenname: M A
  surname: Paul
  fullname: Paul, M A
  organization: Department of Surgery, VU University Medical Center Amsterdam
– sequence: 6
  givenname: E F
  surname: Smit
  fullname: Smit, E F
  organization: Department of Pulmonary Diseases, VU University Medical Center Amsterdam
– sequence: 7
  givenname: P A M
  surname: van Leeuwen
  fullname: van Leeuwen, P A M
  email: PAM.vLeeuwen@vumc.nl
  organization: Department of Surgery, VU University Medical Center Amsterdam
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25572032$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/22234041$$D View this record in MEDLINE/PubMed
BookMark eNp1k1trFTEQxxdR7EUffZWgqE97TDZ79UEoxRsUCtL3MCebnKZkk20uQj-XX9DZ9vTKkX3IkvzmP_9MZg6K5847VRRvGF0xyvvP6kK6VUUZW1Wsflbss7pry6at6fNinw5NXXJKu73iIMYLSvGwq14We1VV8ZrWbL_4exrAEpdTMMl4h_8xz7NVk3IpEuldAuOM2xBXcjJ7e5VdhJQDJDUSDSldEZBmjAS0VjKRywzW4KbXxBqtCDjEspO34gmDIzGO2IyiEpxUgcyQzHW-MYcl15RtMpMfb6RSUJAWP19Qjfw-PntVvNBgo3q9XQ-Ls-_fzo5_lienP34dH52Usu3rVA6yWVPoueLrdq3Wg-wBKOsGyaRuGspVDa1suFZ0TWlDx5qPtIMWNNB6BMoPi683snNeT2qU6ABrJeZgJghXwoMRj0-cORcb_0dwTjnjHQp82goEf5lVTGIyUSprwSmfoxiqtu9aVg9IvntCXvgcsGDXUMPR7eLn_Q20AauEcdpjVrlIiqOqrwbeD6xBqtxBbZRTaBFbRxvcfsSvdvD4jWoycmfAxwcB5wpsOo_e5uWF42Pw7cP63RXutvkQ-LAFIEqwOmA3mHjPNU1XUV7dX0kGH2NQ-g5hVCxDIJYhEMsQCBwC5PkTXhrsO_SHVzP2v1HbQsR5aUIV7t9gd8A_JRYdIw
CitedBy_id crossref_primary_10_1007_s11101_013_9309_1
crossref_primary_10_1080_01635581_2016_1187282
crossref_primary_10_1016_j_clnu_2016_07_015
crossref_primary_10_3389_fnut_2021_686752
crossref_primary_10_1002_ejlt_201800495
crossref_primary_10_1016_j_nut_2014_12_002
crossref_primary_10_2185_jjrm_62_21
crossref_primary_10_3390_nu12113403
crossref_primary_10_1371_journal_pone_0084844
crossref_primary_10_1016_j_critrevonc_2017_09_014
crossref_primary_10_1007_s00432_021_03592_9
crossref_primary_10_1007_s40487_017_0049_z
crossref_primary_10_1097_MJT_0000000000000078
crossref_primary_10_4025_actascianimsci_v44i1_57090
crossref_primary_10_1093_annonc_mdx271
crossref_primary_10_1016_j_clnesp_2024_11_014
crossref_primary_10_1016_j_athoracsur_2012_06_023
crossref_primary_10_1016_j_critrevonc_2014_10_014
crossref_primary_10_3389_fonc_2021_819742
crossref_primary_10_1159_000486347
crossref_primary_10_1016_j_critrevonc_2013_03_006
crossref_primary_10_1080_01635581_2020_1826990
crossref_primary_10_1016_j_fochms_2022_100099
crossref_primary_10_33667_2078_5631_2021_19_64_72
crossref_primary_10_1186_s13643_023_02430_y
crossref_primary_10_3390_jcm5030034
crossref_primary_10_1002_jpen_2599
crossref_primary_10_1093_annonc_mdy114
crossref_primary_10_1055_s_0044_1792185
crossref_primary_10_1111_1750_3841_15776
crossref_primary_10_1016_j_jnim_2016_05_001
crossref_primary_10_3390_cancers14061368
crossref_primary_10_1016_j_clnesp_2021_03_001
crossref_primary_10_1016_j_pcad_2018_03_006
crossref_primary_10_1080_01635581_2019_1634746
crossref_primary_10_1097_MD_0000000000011971
crossref_primary_10_7762_cnr_2023_12_4_304
crossref_primary_10_1111_jocn_17371
crossref_primary_10_1007_s11864_016_0397_1
crossref_primary_10_1007_s00408_022_00536_z
crossref_primary_10_1007_s10120_025_01605_x
crossref_primary_10_1080_10408398_2021_1984199
crossref_primary_10_1016_j_clnu_2020_05_050
crossref_primary_10_1177_15347354241275052
crossref_primary_10_1016_j_apmr_2023_04_013
crossref_primary_10_1016_j_clnu_2014_11_005
crossref_primary_10_1002_jcsm_12626
crossref_primary_10_18632_oncotarget_20168
crossref_primary_10_3389_fnut_2019_00144
crossref_primary_10_1016_j_clnu_2014_03_006
crossref_primary_10_1016_j_nut_2024_112466
crossref_primary_10_1002_jcsm_12228
crossref_primary_10_1016_j_nut_2018_11_014
crossref_primary_10_33667_2078_5631_2020_20_54_59
crossref_primary_10_1007_s00520_022_06837_6
crossref_primary_10_1002_jpen_2052
crossref_primary_10_1016_j_nut_2014_02_003
crossref_primary_10_1016_j_clnu_2017_06_017
crossref_primary_10_1016_j_cct_2017_11_002
crossref_primary_10_3390_nu15122654
crossref_primary_10_1080_01635581_2020_1761408
crossref_primary_10_2196_22006
crossref_primary_10_1016_j_plefa_2017_01_005
crossref_primary_10_1002_cncr_28197
crossref_primary_10_1080_14737140_2022_2082410
crossref_primary_10_17816_clinutr101663
crossref_primary_10_1016_j_clnesp_2018_02_006
crossref_primary_10_1080_01635581_2014_956253
crossref_primary_10_1016_j_clnesp_2021_10_011
crossref_primary_10_1007_s11912_020_00916_9
crossref_primary_10_1002_ejlt_201400025
crossref_primary_10_7762_cnr_2016_5_4_219
crossref_primary_10_1093_annonc_mdu085
crossref_primary_10_1080_01635581_2017_1263748
crossref_primary_10_1016_j_pmrj_2016_03_010
crossref_primary_10_1016_j_clnesp_2019_12_004
crossref_primary_10_1016_j_cmet_2021_05_016
crossref_primary_10_1017_S0029665117003950
crossref_primary_10_1007_s11864_019_0691_9
crossref_primary_10_1016_j_clnu_2021_04_031
crossref_primary_10_1016_j_yclnex_2015_11_001
crossref_primary_10_3390_nu16234090
crossref_primary_10_3390_children1030424
crossref_primary_10_4103_2347_5625_162825
crossref_primary_10_1017_S0029665118000046
crossref_primary_10_1016_j_isci_2024_111601
crossref_primary_10_1007_s11888_015_0268_3
crossref_primary_10_1111_resp_12975
crossref_primary_10_1097_MCO_0b013e32835d2d99
crossref_primary_10_1080_01635581_2014_847473
crossref_primary_10_1016_j_nupar_2024_01_002
crossref_primary_10_3390_ijerph18052399
crossref_primary_10_1007_s10311_024_01720_8
crossref_primary_10_3390_curroncol31010012
crossref_primary_10_1177_0148607115595980
crossref_primary_10_1146_annurev_nutr_071816_064717
crossref_primary_10_1200_CCI_23_00016
crossref_primary_10_1007_s13668_025_00639_y
crossref_primary_10_3390_cancers13061206
crossref_primary_10_1016_j_clnu_2012_05_013
crossref_primary_10_1038_bjc_2012_586
crossref_primary_10_1007_s11626_016_0051_z
crossref_primary_10_1016_j_cllc_2020_10_008
crossref_primary_10_1007_s12603_021_1587_5
crossref_primary_10_1186_s13256_015_0619_3
crossref_primary_10_1155_2024_9361352
crossref_primary_10_1016_j_biochi_2020_08_020
crossref_primary_10_1177_2156587213488788
crossref_primary_10_2217_fon_15_255
crossref_primary_10_1097_MCO_0000000000000236
crossref_primary_10_14694_EdBook_AM_2015_35_e229
Cites_doi 10.1093/jnci/djk093
10.1093/jnci/85.5.365
10.3945/jn.110.121202
10.1093/jn/129.6.1120
10.1053/j.semtcvs.2008.09.007
10.1042/cs0920215
10.1016/j.jclinepi.2005.08.020
10.2307/2531248
10.1177/1534735404264736
10.1016/j.plefa.2007.10.015
10.1158/1055-9965.EPI-08-0589
10.1177/0115426502017004203
10.1016/1047-2797(96)00003-8
10.1016/S1368-8375(98)00049-9
10.1042/cs0980389
10.1038/sj.bjc.6601620
10.1016/S0026-0495(97)90140-2
10.1023/B:EJEP.0000036572.00663.f2
10.1177/1049909108315518
10.1097/CCO.0b013e3283479c66
10.1200/JCO.2005.04.5724
10.1111/j.1600-0838.2007.00740.x
10.1016/S0167-8140(03)00040-9
10.1016/j.jpainsymman.2009.03.006
10.1002/hed.20221
10.1378/chest.89.4_Supplement.225S
10.1207/S15327914NC3602_6
10.1016/S0025-6196(11)60735-0
10.1038/sj.ejcn.1601552
10.1038/sj.bjc.6601781
10.1136/gut.52.10.1479
10.1097/00005768-200009001-00009
10.3945/ajcn.2009.27113G
10.1097/JTO.0b013e3181914d52
10.1002/pbc.21852
ContentType Journal Article
Copyright The Author(s) 2012
2015 INIST-CNRS
COPYRIGHT 2012 Nature Publishing Group
Copyright Nature Publishing Group Mar 2012
Copyright © 2012 Macmillan Publishers Limited 2012 Macmillan Publishers Limited
Copyright_xml – notice: The Author(s) 2012
– notice: 2015 INIST-CNRS
– notice: COPYRIGHT 2012 Nature Publishing Group
– notice: Copyright Nature Publishing Group Mar 2012
– notice: Copyright © 2012 Macmillan Publishers Limited 2012 Macmillan Publishers Limited
DBID C6C
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QP
7RV
7TK
7X2
7X7
7XB
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AEUYN
AFKRA
AN0
ATCPS
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
HCIFZ
K9.
KB0
LK8
M0K
M0S
M1P
M2O
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.1038/ejcn.2011.214
DatabaseName Springer Nature : Open Access Journals
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Nursing & Allied Health Database
Neurosciences Abstracts
Agricultural Science Collection
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
British Nursing Database
Agricultural & Environmental Science Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
ProQuest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Biological Sciences
Agriculture Science Database
ProQuest Health & Medical Collection
Medical Database
Research Library
Biological Science Database
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Agricultural Science Database
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
SciTech Premium Collection
ProQuest Central China
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Agricultural Science Collection
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Agricultural & Environmental Science Collection
ProQuest Research Library
ProQuest Public Health
ProQuest Central Basic
British Nursing Index with Full Text
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
ProQuest Medical Library
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Agricultural Science Database


MEDLINE


Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
Anatomy & Physiology
Diet & Clinical Nutrition
DocumentTitleAlternate n-3 polyunsaturated fatty acids in lung cancer
EISSN 1476-5640
EndPage 404
ExternalDocumentID PMC3303137
2603549791
A282938915
22234041
25572032
10_1038_ejcn_2011_214
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Netherlands
GeographicLocations_xml – name: Netherlands
GroupedDBID ---
-ET
-Q-
.GJ
0R~
29G
2WC
36B
39C
4.4
406
53G
5GY
5RE
6PF
70F
7RV
7X2
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8R4
8R5
A8Z
AACDK
AAHBH
AAIKC
AAMNW
AANZL
AASML
AATNV
AAWTL
AAYZH
ABAKF
ABAWZ
ABBRH
ABCQX
ABDBE
ABDBF
ABFSG
ABJNI
ABLJU
ABOCM
ABRTQ
ABUWG
ABZZP
ACAOD
ACGFO
ACGFS
ACKTT
ACMJI
ACPRK
ACRQY
ACSTC
ACUHS
ACZOJ
ADBBV
ADFRT
ADHUB
AEFQL
AEJRE
AEMSY
AENEX
AEUYN
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFHIU
AFKRA
AFRAH
AFSHS
AGAYW
AGHAI
AGQEE
AHMBA
AHSBF
AHWEU
AI.
AIGIU
AILAN
AIXLP
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
AN0
APEBS
ATCPS
ATHPR
AXYYD
AYFIA
AZQEC
B0M
BAWUL
BBNVY
BENPR
BHPHI
BKEYQ
BKKNO
BKOMP
BNQBC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DNIVK
DPUIP
DU5
DWQXO
E.L
E3Z
EAD
EAP
EAS
EBC
EBD
EBLON
EBO
EBS
ECGQY
EE.
EHN
EIHBH
EIOEI
EJD
EMB
EMK
EMOBN
EPL
EPT
ESX
EX3
F5P
FDQFY
FERAY
FIGPU
FIZPM
FSGXE
FYUFA
GNUQQ
GUQSH
HCIFZ
HMCUK
HZ~
IAG
IAO
ICU
IEA
IHR
IHT
IHW
INH
INR
IOF
ITC
IWAJR
JSO
JZLTJ
KQ8
LGEZI
LOTEE
M0K
M1P
M2O
M7P
NADUK
NAPCQ
NQJWS
NXXTH
O9-
OK1
OVD
P2P
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
Q2X
Q~Q
RNS
RNT
RNTTT
ROL
RXW
SNX
SNYQT
SOHCF
SOJ
SRMVM
SV3
SWTZT
TAE
TAOOD
TBHMF
TDRGL
TEORI
TH9
TR2
TSG
TUS
UKHRP
VH1
WH7
WOW
XOL
ZXP
~02
~8M
~KM
AAYXX
ACMFV
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AEIIB
PMFND
3V.
7QP
7TK
7XB
8FK
K9.
LK8
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c684t-9c5b0a83e3b6beb9c8aa0179c1cf5503e4a6c53fe0b0050d43d07a6afa04da03
IEDL.DBID C6C
ISSN 0954-3007
1476-5640
IngestDate Thu Aug 21 18:30:49 EDT 2025
Fri Sep 05 05:53:33 EDT 2025
Fri Aug 15 20:15:07 EDT 2025
Tue Jun 17 21:00:17 EDT 2025
Thu Jun 12 23:11:54 EDT 2025
Tue Jun 10 20:30:13 EDT 2025
Thu May 22 21:07:43 EDT 2025
Thu Apr 03 07:01:52 EDT 2025
Mon Jul 21 09:16:46 EDT 2025
Tue Jul 01 03:15:16 EDT 2025
Thu Apr 24 23:06:23 EDT 2025
Mon Jul 21 06:06:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords RCT
eicosapenaenoic acid
n-3 fatty acids
lung neoplasms
quality of life
Human
Lung disease
Respiratory disease
Lung cancer
Oral administration
Lipids
Metabolic diseases
Malignant tumor
n-3 fatty acid
Quality of life
Treatment
Unsaturated fatty acid
Bronchus disease
Cancer
Food supplement
Language English
License http://www.springer.com/tdm
CC BY 4.0
This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c684t-9c5b0a83e3b6beb9c8aa0179c1cf5503e4a6c53fe0b0050d43d07a6afa04da03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://www.nature.com/articles/ejcn.2011.214
PMID 22234041
PQID 926535030
PQPubID 33883
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3303137
proquest_miscellaneous_926876149
proquest_journals_926535030
gale_infotracmisc_A282938915
gale_infotracgeneralonefile_A282938915
gale_infotracacademiconefile_A282938915
gale_healthsolutions_A282938915
pubmed_primary_22234041
pascalfrancis_primary_25572032
crossref_primary_10_1038_ejcn_2011_214
crossref_citationtrail_10_1038_ejcn_2011_214
springer_journals_10_1038_ejcn_2011_214
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-03-01
PublicationDateYYYYMMDD 2012-03-01
PublicationDate_xml – month: 03
  year: 2012
  text: 2012-03-01
  day: 01
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: Basingstoke
– name: England
PublicationTitle European journal of clinical nutrition
PublicationTitleAbbrev Eur J Clin Nutr
PublicationTitleAlternate Eur J Clin Nutr
PublicationYear 2012
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Carlson (CR36) 2009; 89
Paccagnella, Morassutti, Rosti (CR9) 2011; 23
Zeger, Liang (CR28) 1986; 42
Ravasco, Monteiro-Grillo, Camilo (CR33) 2003; 67
Lowe, Watanabe, Baracos, Courneya (CR38) 2009; 38
Barber (CR10) 2002; 17
Ravasco, Monteiro-Grillo, Marques, Camilo (CR8) 2005; 27
Gibney, Elia, Jebb, Murgatroyd, Jennings (CR39) 1997; 46
Twisk (CR27) 2004; 19
Gupta, Lis, Granick, Grutsch, Vashi, Lammersfeld (CR34) 2006; 59
Guarcello, Riso, Buosi, D’Andrea (CR14) 2007; 25
Slootmaker, Chinapaw, Schuit, van Mechelen, Koppes (CR24) 2009; 19
van Meerbeeck, Kramer, Van Schil, Legrand, Smit, Schramel (CR5) 2007; 99
Wigmore, Fearon, Maingay, Ross (CR29) 1997; 92
Ross, Ashley, Norton, Priest, Waters, Eisen (CR6) 2004; 90
Karnofsky, Burchenal (CR22) 1949
Yates, Chalmer, McKegney (CR21) 1980; 45
Twisk, Kemper, Mellenbergh, van Mechelen, Post (CR26) 1996; 6
Molina, Yang, Cassivi, Schild, Adjei (CR1) 2008; 83
Jho, Cole, Lee, Espat (CR12) 2004; 3
Mountain (CR2) 1986; 89
Fearon, Barber, Moses, Ahmedzai, Taylor, Tisdale (CR18) 2006; 24
Bayram, Erbey, Celik, Nelson, Tanyeli (CR15) 2009; 52
Aaronson, Ahmedzai, Bergman, Bullinger, Cull, Duez (CR20) 1993; 85
Calder (CR13) 2007; 77
Fearon, von Meyenfeldt, Moses, Van Geenen, Roy, Gouma (CR17) 2003; 52
de Graeff, de Leeuw, Ros, Hordijk, Blijham, Winnubst (CR7) 1999; 35
Price, Azzoli, Gaspar (CR3) 2008; 20
De Leyn, Vansteenkiste, Lievens, Van, Nafteux, Decker (CR4) 2009; 4
Barber, McMillan, Preston, Ross, Fearon (CR30) 2000; 98
Isenring, Bauer, Capra (CR35) 2003; 57
Meij van der, Langius, Smit, Spreeuwenberg, von Blomberg, Heijboer (CR19) 2010; 140
CR40
Moses, Slater, Preston, Barber, Fearon (CR16) 2004; 90
Bennani-Baiti, Davis (CR11) 2008; 25
Mathiowetz, Kashman, Volland, Weber, Dowe, Rogers (CR23) 1985; 66
Barber, Ross, Preston, Shenkin, Fearon (CR31) 1999; 129
Coups, Park, Feinstein, Steingart, Egleston, Wilson (CR37) 2009; 18
Ainsworth, Haskell, Whitt, Irwin, Swartz, Strath (CR25) 2000; 32
Wigmore, Barber, Ross, Tisdale, Fearon (CR32) 2000; 36
JP van Meerbeeck (BFejcn2011214_CR5) 2007; 99
DA Karnofsky (BFejcn2011214_CR22) 1949
NK Aaronson (BFejcn2011214_CR20) 1993; 85
JR Molina (BFejcn2011214_CR1) 2008; 83
SJ Wigmore (BFejcn2011214_CR29) 1997; 92
BE Ainsworth (BFejcn2011214_CR25) 2000; 32
CF Mountain (BFejcn2011214_CR2) 1986; 89
KC Fearon (BFejcn2011214_CR17) 2003; 52
E Isenring (BFejcn2011214_CR35) 2003; 57
JW Twisk (BFejcn2011214_CR26) 1996; 6
SE Carlson (BFejcn2011214_CR36) 2009; 89
N Bennani-Baiti (BFejcn2011214_CR11) 2008; 25
V Mathiowetz (BFejcn2011214_CR23) 1985; 66
A de Graeff (BFejcn2011214_CR7) 1999; 35
AW Moses (BFejcn2011214_CR16) 2004; 90
JW Twisk (BFejcn2011214_CR27) 2004; 19
E Gibney (BFejcn2011214_CR39) 1997; 46
DH Jho (BFejcn2011214_CR12) 2004; 3
P Ravasco (BFejcn2011214_CR33) 2003; 67
BFejcn2011214_CR40
EJ Coups (BFejcn2011214_CR37) 2009; 18
PC Calder (BFejcn2011214_CR13) 2007; 77
KC Fearon (BFejcn2011214_CR18) 2006; 24
PJ Ross (BFejcn2011214_CR6) 2004; 90
A Paccagnella (BFejcn2011214_CR9) 2011; 23
JW Yates (BFejcn2011214_CR21) 1980; 45
D Gupta (BFejcn2011214_CR34) 2006; 59
P Ravasco (BFejcn2011214_CR8) 2005; 27
I Bayram (BFejcn2011214_CR15) 2009; 52
MD Barber (BFejcn2011214_CR31) 1999; 129
MD Barber (BFejcn2011214_CR10) 2002; 17
SM Slootmaker (BFejcn2011214_CR24) 2009; 19
SS Lowe (BFejcn2011214_CR38) 2009; 38
KA Price (BFejcn2011214_CR3) 2008; 20
BS Meij van der (BFejcn2011214_CR19) 2010; 140
SJ Wigmore (BFejcn2011214_CR32) 2000; 36
MD Barber (BFejcn2011214_CR30) 2000; 98
P De Leyn (BFejcn2011214_CR4) 2009; 4
M Guarcello (BFejcn2011214_CR14) 2007; 25
SL Zeger (BFejcn2011214_CR28) 1986; 42
19190151 - Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):664-72
3514171 - Chest. 1986 Apr;89(4 Suppl):225S-233S
15469034 - Eur J Epidemiol. 2004;19(8):769-76
3970660 - Arch Phys Med Rehabil. 1985 Feb;66(2):69-74
10731472 - Clin Sci (Lond). 2000 Apr;98(4):389-99
15920748 - Head Neck. 2005 Aug;27(8):659-68
10356075 - J Nutr. 1999 Jun;129(6):1120-5
19090549 - Pediatr Blood Cancer. 2009 May;52(5):571-4
15165497 - Integr Cancer Ther. 2004 Jun;3(2):98-111
21552123 - Curr Opin Oncol. 2011 Jul;23(4):322-30
16214988 - Nutr Clin Pract. 2002 Aug;17(4):203-9
18032006 - Prostaglandins Leukot Essent Fatty Acids. 2007 Nov-Dec;77(5-6):327-35
19321568 - Am J Clin Nutr. 2009 May;89(5):1523S-1529S
10211307 - Oral Oncol. 1999 Jan;35(1):27-32
10993420 - Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504
18266793 - Scand J Med Sci Sports. 2009 Feb;19(1):36-43
9059324 - Clin Sci (Lond). 1997 Feb;92(2):215-21
7370963 - Cancer. 1980 Apr 15;45(8):2220-4
10890028 - Nutr Cancer. 2000;36(2):177-84
12970142 - Gut. 2003 Oct;52(10):1479-86
3719049 - Biometrics. 1986 Mar;42(1):121-30
19775864 - J Pain Symptom Manage. 2009 Nov;38(5):785-96
17374834 - J Natl Cancer Inst. 2007 Mar 21;99(6):442-50
19038729 - Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):204-9
20739445 - J Nutr. 2010 Oct;140(10):1774-80
19096308 - J Thorac Oncol. 2009 Jan;4(1):62-8
15138470 - Br J Cancer. 2004 May 17;90(10):1905-11
16765273 - J Clin Epidemiol. 2006 Jul;59(7):704-9
8433390 - J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
16849754 - J Clin Oncol. 2006 Jul 20;24(21):3401-7
8827160 - Ann Epidemiol. 1996 May;6(3):246-56
12812853 - Radiother Oncol. 2003 May;67(2):213-20
12571664 - Eur J Clin Nutr. 2003 Feb;57(2):305-9
18452692 - Mayo Clin Proc. 2008 May;83(5):584-94
18403577 - Am J Hosp Palliat Care. 2008 Oct-Nov;25(5):407-11
14997196 - Br J Cancer. 2004 Mar 8;90(5):996-1002
9439535 - Metabolism. 1997 Dec;46(12):1412-7
References_xml – volume: 99
  start-page: 442
  year: 2007
  end-page: 450
  ident: CR5
  article-title: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djk093
– volume: 85
  start-page: 365
  year: 1993
  end-page: 376
  ident: CR20
  article-title: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/85.5.365
– volume: 140
  start-page: 1774
  year: 2010
  end-page: 1780
  ident: CR19
  article-title: Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment
  publication-title: J Nutr
  doi: 10.3945/jn.110.121202
– volume: 129
  start-page: 1120
  year: 1999
  end-page: 1125
  ident: CR31
  article-title: Fish oil-enriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer
  publication-title: J Nutr
  doi: 10.1093/jn/129.6.1120
– volume: 20
  start-page: 204
  year: 2008
  end-page: 209
  ident: CR3
  article-title: Chemoradiation for unresectable stage III non-small cell lung cancer
  publication-title: Semin Thorac Cardiovasc Surg
  doi: 10.1053/j.semtcvs.2008.09.007
– volume: 92
  start-page: 215
  year: 1997
  end-page: 221
  ident: CR29
  article-title: Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6
  publication-title: Clin Sci (Lond)
  doi: 10.1042/cs0920215
– volume: 59
  start-page: 704
  year: 2006
  end-page: 709
  ident: CR34
  article-title: Malnutrition was associated with poor quality of life in colorectal cancer: a retrospective analysis
  publication-title: J Clin Epidemiol
  doi: 10.1016/j.jclinepi.2005.08.020
– volume: 42
  start-page: 121
  year: 1986
  end-page: 130
  ident: CR28
  article-title: Longitudinal data analysis for discrete and continuous outcomes
  publication-title: Biometrics
  doi: 10.2307/2531248
– volume: 3
  start-page: 98
  year: 2004
  end-page: 111
  ident: CR12
  article-title: Role of omega-3 fatty acid supplementation in inflammation and malignancy
  publication-title: Integr Cancer Ther
  doi: 10.1177/1534735404264736
– volume: 77
  start-page: 327
  year: 2007
  end-page: 335
  ident: CR13
  article-title: Immunomodulation by omega-3 fatty acids
  publication-title: Prostaglandins Leukot Essent Fatty Acids
  doi: 10.1016/j.plefa.2007.10.015
– volume: 18
  start-page: 664
  year: 2009
  end-page: 672
  ident: CR37
  article-title: Physical activity among lung cancer survivors: changes across the cancer trajectory and associations with quality of life
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-08-0589
– volume: 17
  start-page: 203
  year: 2002
  end-page: 209
  ident: CR10
  article-title: The pathophysiology and treatment of cancer cachexia
  publication-title: Nutr Clin Prac
  doi: 10.1177/0115426502017004203
– volume: 6
  start-page: 246
  year: 1996
  end-page: 256
  ident: CR26
  article-title: Relation between the longitudinal development of lipoprotein levels and lifestyle parameters during adolescence and young adulthood
  publication-title: Ann Epidemiol
  doi: 10.1016/1047-2797(96)00003-8
– ident: CR40
– volume: 35
  start-page: 27
  year: 1999
  end-page: 32
  ident: CR7
  article-title: A prospective study on quality of life of patients with cancer of the oral cavity or oropharynx treated with surgery with or without radiotherapy
  publication-title: Oral Oncol
  doi: 10.1016/S1368-8375(98)00049-9
– volume: 98
  start-page: 389
  year: 2000
  end-page: 399
  ident: CR30
  article-title: Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement
  publication-title: Clin Sci (Lond)
  doi: 10.1042/cs0980389
– volume: 90
  start-page: 996
  year: 2004
  end-page: 1002
  ident: CR16
  article-title: Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6601620
– volume: 46
  start-page: 1412
  year: 1997
  end-page: 1417
  ident: CR39
  article-title: Total energy expenditure in patients with small-cell lung cancer: results of a validated study using the bicarbonate-urea method
  publication-title: Metabolism
  doi: 10.1016/S0026-0495(97)90140-2
– volume: 19
  start-page: 769
  year: 2004
  end-page: 776
  ident: CR27
  article-title: Longitudinal data analysis. A comparison between generalized estimating equations and random coefficient analysis
  publication-title: Eur J Epidemiol
  doi: 10.1023/B:EJEP.0000036572.00663.f2
– volume: 25
  start-page: 407
  year: 2008
  end-page: 411
  ident: CR11
  article-title: Cytokines and cancer anorexia cachexia syndrome
  publication-title: Am J Hosp Palliat Care
  doi: 10.1177/1049909108315518
– volume: 23
  start-page: 322
  year: 2011
  end-page: 330
  ident: CR9
  article-title: Nutritional intervention for improving treatment tolerance in cancer patients
  publication-title: Curr Opin Oncol
  doi: 10.1097/CCO.0b013e3283479c66
– volume: 24
  start-page: 3401
  year: 2006
  end-page: 3407
  ident: CR18
  article-title: Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.04.5724
– volume: 19
  start-page: 36
  year: 2009
  end-page: 43
  ident: CR24
  article-title: Concurrent validity of the PAM accelerometer relative to the MTI Actigraph using oxygen consumption as a reference
  publication-title: Scand J Med Sci Sports
  doi: 10.1111/j.1600-0838.2007.00740.x
– volume: 67
  start-page: 213
  year: 2003
  end-page: 220
  ident: CR33
  article-title: Does nutrition influence quality of life in cancer patients undergoing radiotherapy?
  publication-title: Radiother Oncol
  doi: 10.1016/S0167-8140(03)00040-9
– volume: 38
  start-page: 785
  year: 2009
  end-page: 796
  ident: CR38
  article-title: Associations between physical activity and quality of life in cancer patients receiving palliative care: a pilot survey
  publication-title: J Pain Symptom Manage
  doi: 10.1016/j.jpainsymman.2009.03.006
– volume: 45
  start-page: 2220
  year: 1980
  end-page: 2224
  ident: CR21
  article-title: Evaluation of patients with advanced cancer using the Karnofsky performance status
  publication-title: Nat Rev Cancer
– volume: 27
  start-page: 659
  year: 2005
  end-page: 668
  ident: CR8
  article-title: Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy
  publication-title: Head Neck
  doi: 10.1002/hed.20221
– volume: 89
  start-page: 225S
  year: 1986
  end-page: 233S
  ident: CR2
  article-title: A new international staging system for lung cancer
  publication-title: Chest
  doi: 10.1378/chest.89.4_Supplement.225S
– volume: 25
  start-page: 25
  year: 2007
  end-page: 30
  ident: CR14
  article-title: EPA-enriched oral nutritional suport in patients with lung cancer: effects on nutritional status and quality of life
  publication-title: Nutr Ther Metab
– volume: 36
  start-page: 177
  year: 2000
  end-page: 184
  ident: CR32
  article-title: Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer
  publication-title: Nutr Cancer
  doi: 10.1207/S15327914NC3602_6
– volume: 83
  start-page: 584
  year: 2008
  end-page: 594
  ident: CR1
  article-title: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship
  publication-title: Mayo Clin Proc
  doi: 10.1016/S0025-6196(11)60735-0
– volume: 66
  start-page: 69
  year: 1985
  end-page: 74
  ident: CR23
  article-title: Grip and pinch strength: normative data for adults
  publication-title: Arch Phys Med Rehabil
– volume: 57
  start-page: 305
  year: 2003
  end-page: 309
  ident: CR35
  article-title: The scored Patient-generated Subjective Global Assessment (PG-SGA) and its association with quality of life in ambulatory patients receiving radiotherapy
  publication-title: Eur J Clin Nutr
  doi: 10.1038/sj.ejcn.1601552
– volume: 90
  start-page: 1905
  year: 2004
  end-page: 1911
  ident: CR6
  article-title: Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6601781
– volume: 52
  start-page: 1479
  year: 2003
  end-page: 1486
  ident: CR17
  article-title: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial
  publication-title: Gut
  doi: 10.1136/gut.52.10.1479
– volume: 32
  start-page: S498
  year: 2000
  end-page: S504
  ident: CR25
  article-title: Compendium of physical activities: an update of activity codes and MET intensities
  publication-title: Med Sci Sports Exerc
  doi: 10.1097/00005768-200009001-00009
– volume: 89
  start-page: 1523S
  year: 2009
  end-page: 1529S
  ident: CR36
  article-title: Early determinants of development: a lipid perspective
  publication-title: Am J Clin Nutr
  doi: 10.3945/ajcn.2009.27113G
– volume: 4
  start-page: 62
  year: 2009
  end-page: 68
  ident: CR4
  article-title: Survival after trimodality treatment for superior sulcus and central T4 non-small cell lung cancer
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e3181914d52
– volume: 52
  start-page: 571
  year: 2009
  end-page: 574
  ident: CR15
  article-title: The use of a protein and energy dense eicosapentaenoic acid containing supplement for malignancy-related weight loss in children
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.21852
– start-page: 196
  year: 1949
  ident: CR22
  article-title: Evaluation of chemotherapeutic agents
  publication-title: The Clinical Evaluation of Chemotherapeutic Agents in Cancer
– volume: 52
  start-page: 1479
  year: 2003
  ident: BFejcn2011214_CR17
  publication-title: Gut
  doi: 10.1136/gut.52.10.1479
– volume: 140
  start-page: 1774
  year: 2010
  ident: BFejcn2011214_CR19
  publication-title: J Nutr
  doi: 10.3945/jn.110.121202
– ident: BFejcn2011214_CR40
– volume: 67
  start-page: 213
  year: 2003
  ident: BFejcn2011214_CR33
  publication-title: Radiother Oncol
  doi: 10.1016/S0167-8140(03)00040-9
– volume: 92
  start-page: 215
  year: 1997
  ident: BFejcn2011214_CR29
  publication-title: Clin Sci (Lond)
  doi: 10.1042/cs0920215
– volume: 59
  start-page: 704
  year: 2006
  ident: BFejcn2011214_CR34
  publication-title: J Clin Epidemiol
  doi: 10.1016/j.jclinepi.2005.08.020
– volume: 23
  start-page: 322
  year: 2011
  ident: BFejcn2011214_CR9
  publication-title: Curr Opin Oncol
  doi: 10.1097/CCO.0b013e3283479c66
– volume: 25
  start-page: 25
  year: 2007
  ident: BFejcn2011214_CR14
  publication-title: Nutr Ther Metab
– volume: 6
  start-page: 246
  year: 1996
  ident: BFejcn2011214_CR26
  publication-title: Ann Epidemiol
  doi: 10.1016/1047-2797(96)00003-8
– volume: 90
  start-page: 1905
  year: 2004
  ident: BFejcn2011214_CR6
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6601781
– volume: 32
  start-page: S498
  year: 2000
  ident: BFejcn2011214_CR25
  publication-title: Med Sci Sports Exerc
  doi: 10.1097/00005768-200009001-00009
– volume: 19
  start-page: 36
  year: 2009
  ident: BFejcn2011214_CR24
  publication-title: Scand J Med Sci Sports
  doi: 10.1111/j.1600-0838.2007.00740.x
– volume: 25
  start-page: 407
  year: 2008
  ident: BFejcn2011214_CR11
  publication-title: Am J Hosp Palliat Care
  doi: 10.1177/1049909108315518
– volume: 35
  start-page: 27
  year: 1999
  ident: BFejcn2011214_CR7
  publication-title: Oral Oncol
  doi: 10.1016/S1368-8375(98)00049-9
– start-page: 196
  volume-title: The Clinical Evaluation of Chemotherapeutic Agents in Cancer
  year: 1949
  ident: BFejcn2011214_CR22
– volume: 66
  start-page: 69
  year: 1985
  ident: BFejcn2011214_CR23
  publication-title: Arch Phys Med Rehabil
– volume: 85
  start-page: 365
  year: 1993
  ident: BFejcn2011214_CR20
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/85.5.365
– volume: 19
  start-page: 769
  year: 2004
  ident: BFejcn2011214_CR27
  publication-title: Eur J Epidemiol
  doi: 10.1023/B:EJEP.0000036572.00663.f2
– volume: 90
  start-page: 996
  year: 2004
  ident: BFejcn2011214_CR16
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6601620
– volume: 129
  start-page: 1120
  year: 1999
  ident: BFejcn2011214_CR31
  publication-title: J Nutr
  doi: 10.1093/jn/129.6.1120
– volume: 89
  start-page: 1523S
  year: 2009
  ident: BFejcn2011214_CR36
  publication-title: Am J Clin Nutr
  doi: 10.3945/ajcn.2009.27113G
– volume: 57
  start-page: 305
  year: 2003
  ident: BFejcn2011214_CR35
  publication-title: Eur J Clin Nutr
  doi: 10.1038/sj.ejcn.1601552
– volume: 89
  start-page: 225S
  year: 1986
  ident: BFejcn2011214_CR2
  publication-title: Chest
  doi: 10.1378/chest.89.4_Supplement.225S
– volume: 20
  start-page: 204
  year: 2008
  ident: BFejcn2011214_CR3
  publication-title: Semin Thorac Cardiovasc Surg
  doi: 10.1053/j.semtcvs.2008.09.007
– volume: 99
  start-page: 442
  year: 2007
  ident: BFejcn2011214_CR5
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djk093
– volume: 52
  start-page: 571
  year: 2009
  ident: BFejcn2011214_CR15
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.21852
– volume: 24
  start-page: 3401
  year: 2006
  ident: BFejcn2011214_CR18
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.04.5724
– volume: 77
  start-page: 327
  year: 2007
  ident: BFejcn2011214_CR13
  publication-title: Prostaglandins Leukot Essent Fatty Acids
  doi: 10.1016/j.plefa.2007.10.015
– volume: 3
  start-page: 98
  year: 2004
  ident: BFejcn2011214_CR12
  publication-title: Integr Cancer Ther
  doi: 10.1177/1534735404264736
– volume: 45
  start-page: 2220
  year: 1980
  ident: BFejcn2011214_CR21
  publication-title: Nat Rev Cancer
– volume: 18
  start-page: 664
  year: 2009
  ident: BFejcn2011214_CR37
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-08-0589
– volume: 83
  start-page: 584
  year: 2008
  ident: BFejcn2011214_CR1
  publication-title: Mayo Clin Proc
  doi: 10.1016/S0025-6196(11)60735-0
– volume: 17
  start-page: 203
  year: 2002
  ident: BFejcn2011214_CR10
  publication-title: Nutr Clin Prac
  doi: 10.1177/0115426502017004203
– volume: 4
  start-page: 62
  year: 2009
  ident: BFejcn2011214_CR4
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e3181914d52
– volume: 46
  start-page: 1412
  year: 1997
  ident: BFejcn2011214_CR39
  publication-title: Metabolism
  doi: 10.1016/S0026-0495(97)90140-2
– volume: 42
  start-page: 121
  year: 1986
  ident: BFejcn2011214_CR28
  publication-title: Biometrics
  doi: 10.2307/2531248
– volume: 36
  start-page: 177
  year: 2000
  ident: BFejcn2011214_CR32
  publication-title: Nutr Cancer
  doi: 10.1207/S15327914NC3602_6
– volume: 98
  start-page: 389
  year: 2000
  ident: BFejcn2011214_CR30
  publication-title: Clin Sci (Lond)
  doi: 10.1042/cs0980389
– volume: 38
  start-page: 785
  year: 2009
  ident: BFejcn2011214_CR38
  publication-title: J Pain Symptom Manage
  doi: 10.1016/j.jpainsymman.2009.03.006
– volume: 27
  start-page: 659
  year: 2005
  ident: BFejcn2011214_CR8
  publication-title: Head Neck
  doi: 10.1002/hed.20221
– reference: 10211307 - Oral Oncol. 1999 Jan;35(1):27-32
– reference: 12970142 - Gut. 2003 Oct;52(10):1479-86
– reference: 19096308 - J Thorac Oncol. 2009 Jan;4(1):62-8
– reference: 16849754 - J Clin Oncol. 2006 Jul 20;24(21):3401-7
– reference: 17374834 - J Natl Cancer Inst. 2007 Mar 21;99(6):442-50
– reference: 9059324 - Clin Sci (Lond). 1997 Feb;92(2):215-21
– reference: 10890028 - Nutr Cancer. 2000;36(2):177-84
– reference: 15138470 - Br J Cancer. 2004 May 17;90(10):1905-11
– reference: 12571664 - Eur J Clin Nutr. 2003 Feb;57(2):305-9
– reference: 14997196 - Br J Cancer. 2004 Mar 8;90(5):996-1002
– reference: 18032006 - Prostaglandins Leukot Essent Fatty Acids. 2007 Nov-Dec;77(5-6):327-35
– reference: 19321568 - Am J Clin Nutr. 2009 May;89(5):1523S-1529S
– reference: 19775864 - J Pain Symptom Manage. 2009 Nov;38(5):785-96
– reference: 18452692 - Mayo Clin Proc. 2008 May;83(5):584-94
– reference: 20739445 - J Nutr. 2010 Oct;140(10):1774-80
– reference: 8433390 - J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
– reference: 3970660 - Arch Phys Med Rehabil. 1985 Feb;66(2):69-74
– reference: 19190151 - Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):664-72
– reference: 9439535 - Metabolism. 1997 Dec;46(12):1412-7
– reference: 15920748 - Head Neck. 2005 Aug;27(8):659-68
– reference: 16214988 - Nutr Clin Pract. 2002 Aug;17(4):203-9
– reference: 19090549 - Pediatr Blood Cancer. 2009 May;52(5):571-4
– reference: 15165497 - Integr Cancer Ther. 2004 Jun;3(2):98-111
– reference: 10356075 - J Nutr. 1999 Jun;129(6):1120-5
– reference: 21552123 - Curr Opin Oncol. 2011 Jul;23(4):322-30
– reference: 16765273 - J Clin Epidemiol. 2006 Jul;59(7):704-9
– reference: 19038729 - Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):204-9
– reference: 3719049 - Biometrics. 1986 Mar;42(1):121-30
– reference: 15469034 - Eur J Epidemiol. 2004;19(8):769-76
– reference: 10993420 - Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504
– reference: 8827160 - Ann Epidemiol. 1996 May;6(3):246-56
– reference: 18266793 - Scand J Med Sci Sports. 2009 Feb;19(1):36-43
– reference: 12812853 - Radiother Oncol. 2003 May;67(2):213-20
– reference: 7370963 - Cancer. 1980 Apr 15;45(8):2220-4
– reference: 18403577 - Am J Hosp Palliat Care. 2008 Oct-Nov;25(5):407-11
– reference: 3514171 - Chest. 1986 Apr;89(4 Suppl):225S-233S
– reference: 10731472 - Clin Sci (Lond). 2000 Apr;98(4):389-99
SSID ssj0014772
Score 2.3945808
Snippet Background/Objectives: Our objective was to investigate effects of an oral nutritional supplement containing n-3 polyunsaturated fatty acids (FAs) on quality...
Our objective was to investigate effects of an oral nutritional supplement containing n-3 polyunsaturated fatty acids (FAs) on quality of life, performance...
BACKGROUND/OBJECTIVES: Our objective was to investigate effects of an oral nutritional supplement containing n-3 polyunsaturated fatty acids (FAs) on quality...
SUBJECTS/METHODS: In a double-blind experiment, 40 patients with stage III NSCLC were randomised to receive 2 cans/day of a protein-and energy-dense oral...
Background/Objectives: Our objective was to investigate effects of an oral nutritional supplement containing n-3 polyunsaturated fatty acids (FAs) on quality...
SourceID pubmedcentral
proquest
gale
pubmed
pascalfrancis
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 399
SubjectTerms 692/699/67/1612
692/700/459/1994
692/700/784
Activities of Daily Living
Aged
Biological and medical sciences
Cancer patients
Carcinoma, Non-Small-Cell Lung
Clinical Nutrition
Cognition - drug effects
Cognitive ability
Combined Modality Therapy
Development and progression
Dietary Proteins - administration & dosage
Dietary Supplements
Docosahexaenoic Acids - pharmacology
Double-Blind Method
Eicosapentaenoic Acid - pharmacology
Energy Intake
Epidemiology
Fatty acids
Fatty Acids, Omega-3 - pharmacology
Feeding. Feeding behavior
Female
Fundamental and applied biological sciences. Psychology
Global health
Hand Strength
Health aspects
Health Status
Humans
Internal Medicine
Interpersonal Relations
Intervention
Lung cancer
Male
Medical sciences
Medicine
Medicine & Public Health
Metabolic Diseases
Middle Aged
Motor Activity
Neoplasm Staging
Original
original-article
Physical Fitness
Physiological aspects
Pneumology
Polyunsaturated fatty acids
Public Health
Quality of Life
Tumors of the respiratory system and mediastinum
Unsaturated fatty acids
Vertebrates: anatomy and physiology, studies on body, several organs or systems
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELege0FCCDY-wsbwAyovREtrOx-8oDI2TUgUNBVpb5HjOFDUOWVJH_p38Q9yZzuZAoW3Kj45jnv--c53_h0hr2IpmIrx3E1lIsRyFqEshAirolCTLCtVZEsnfJrHF1_5xytx5XNzGp9W2WGiBeqyVnhGfpJNY8EEqOS79c8Qi0ZhcNVX0LhL9gCBUzEie-_P5l8u-zACT2z1JjAj8Pg_SjzJZsTSE_1DGcfgOZ3wwabkofn-WjYwTZWrb7HLAP07j_KPYKrdo84fkgfeuKQzpw2PyB1t9snBzIBjfb2lY2rTPe05-j4JPix1C888MeiKzjte_gPy6zO8h5ruAfxusPinPUlsKGa3u7oS1ISMruvVdmMaJAgFu7WklWzbLZVqWTZU2mwR6m5ubmld0dWy0lQaEIMNtescDN5NQ5eGrgB6qEJFvKGe8bWh7iYltamP13XpuuoT5N9Cb_TydPGYLM7PFqcXoa_uEKo45W2YKVFEMmWaFXGhi0ylUiI8qImqwG1imstYCVbpCJEiKjkro0TGspIRL2XEnpCRqY1-RigHnyerUlYxpbkC_0knlZJZpFJWCC7TgLzp_t1ceeZzLMCxym0EnqU5KkOOypCDMgRk3IuvHeXHvwRfoqrk7sZqDxX5DKPTGP8VAXltJRAs4I1K-jsPMG6k3RpIjgeS3xzp-C7Bo4EgoIEaNB8P9Lb_AnAdMeI-Dchhp8i5h6sm7xdXQGjfij1jBp7R9caKwMYJ_nRAnjqtv-0aTEwe8UlAksF66AWQwnzYYpbfLZU5Y8gdmsA8dSvndlA75_z5f4d_SO6B4NTlCB6RUXuz0S_AaGyLYw8NvwG07nFH
  priority: 102
  providerName: ProQuest
Title Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT
URI https://link.springer.com/article/10.1038/ejcn.2011.214
https://www.ncbi.nlm.nih.gov/pubmed/22234041
https://www.proquest.com/docview/926535030
https://www.proquest.com/docview/926876149
https://pubmed.ncbi.nlm.nih.gov/PMC3303137
Volume 66
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgkxDShKDjI2yUe0DlhQi3zidvpWyakFbQVKS-RY7jQFGXVEv70L-Lf5A728kUGBIvVVT_6jju5Xz23f2OsTeRDIWK6NxNpaFP5Sx8mYehX-a5GqdpobgpnXA5jy6-BZ-X4dIlqzcurNJSWho13UaHvdc_VWUJNydUtvqQWNuJKn8WzTqnQRCbWk1oNNBhP48dpSYXSf_nvSXIKeKjjWxwUkpbzeIuc_PvqMk_XKdmRTp_zB45UxKmdvBP2D1dDdjxFJ-rvt7DCExwpzk1HzDv00pv8TtHA7qGecvCP2APLp1_fcCO7Cke2OSkY_brCw4BqhaL1w1VATVHig1QmLstMAGVL2BTr_e7qqFpRQO2gFJut3uQalU0IE3YCNgUzj3UJaxXpQZZIQxX1rZztHx3DawqWKMOAkUSeQOO-rUBm1IJJgbyui5sV12k_AfsDa5mi6dscX62mF34rsyDr6Ik2PqpCnMuE6FFHuU6T1UiJekJNVYl7p-EDmSkQlFqTiqDF4EoeCwjWUoeFJKLZ-ygqiv9gkGAm5-0TEQplA4UbqR0XCqZcpWIPAxk4rF37R-fKUeBTpU41plxxYskIznJSE4ylBOPjTr4xnJ__Av4mqQos6mrnc7IpuSmJkdw6LG3BkFaA--opEt-wHET_1YPOeohv1v28buApz0gqgXVax72RLp7AtxDkut94rGTVsYzp7eaLJ1EocA55x6DrpV6plC8Stc7A8EVFDfWHntuX4jbrtHWDHgw9ljce1U6AHGZ91uq1Q_DaS4EkYjGOE_tS3U7qDvn_OV_I0_YQ7yc2MDBU3awvdnpV2hJbvMhux8vY_xMZuMhO_x4Nv96NTQ65Tdiynhx
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfG9gASQrDBCBvbPUB5IVoa5xMJobIPdWwraCrS3iLHcaCoS8rSCvV_4o1_kDs7yRQYvO2tSq6OE_98vvOdf8fYi0D4XAa07yZj36ZyFrZIfd_O01T24ziTji6dcDYKhp-9Dxf-xQr72ZyFobTKRidqRZ2VkvbI92I38LmPkHw3-25T0SgKrjYVNAwqTtTyB3ps1dvjAxzel657dDjeH9p1UQFbBpE3t2Ppp46IuOJpkKo0lpEQhErZlzla61x5IpA-z5VDAHUyj2dOKAKRC8fLhMOx2TtsDY2MGOfQ2vvD0afzNmrhhbpYFFotFG1wwprT0-HRnvomC0MY6va9zhpYrwT3Z6LCUclNOY2b7N2_0zb_iN3qJfHoIXtQ27IwMOB7xFZUsc42BgX68ZdL6IHOLtXb9uvMOpioOV6reUinMGrKAGywXx_xOVA0F_B3RbVG9cZlBZRMb8pYQGFzmJXT5aKoiI8UzeQMcjGfL0HISVaB0MkpYA6KLqHMYTrJFYgCxXD9bhpH-3pRwaSAKWo6kIT7K6gJZiswBzdBZ1pelplpqs3Hf4Otwfn--DEb38a4P2GrRVmopww8dLHiPOI5l8qT6K6pMJcidmTEU98TkcVeN6ObyJponep9TBMd8OdRQmBICAwJgsFivVZ8ZhhG_iW4S1BJzAHZVjMlAwqGU7jZt9grLUG6CZ8oRX3EAvtNLF8dyV5H8ovhOL9JcLsjiMpHdm7vdHDbvgF6qhTgdy221QA5qbVjlbRz2WLQ3qWWKeGvUOVCi-A6je67xTYN6q-bRovWc7y-xcLOfGgFiDG9e6eYfNXM6ZwTVWmI36mZOdeduvGbP_tv93fZ3eH47DQ5PR6dbLF7-CfXpCdus9X51UI9R3t1nu7UagJYcsuK6TcFSa7E
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwELbGkBASQrDBCBvbPUB5IWpa5ycSQlXLtDEoCBVpb5HjOFDUJWVJhfp38cKfx52dZAoU3vZWJVfHic_nO9_5-xh76guPS5_23WTk2URnYYvE8-wsSeQgilLpaOqE91P_5LP79tw732K_mrMwVFbZ2ERtqNNC0h55Pxr6HvdQJftZXRXxcXL8evndJgIpSrQ2bBpGQ87U-gdGb-Wr0wkO9bPh8PjNbHxi1wQDtvRDt7Ij6SWOCLniiZ-oJJKhEKShciAz9Ny5coUvPZ4ph5TVSV2eOoHwRSYcNxUOx2ZvsJsBD0IijQjHbXHJwA00bRT6L5R3cIIa3dPhYV99k7mBDh0O3M5qWK8Jd5aixPHJDLHGJs_37wLOP7K4enE8vsfu1l4tjIwa3mdbKt9hu6McI_qLNfRA15nqDfwdZk3mqsJrNSLpAqYNIcAu-_kBnwN5cwF_l8Q6qrcwS6CyekNoAbnNYVks1qu8JGRSdJhTyERVrUHIeVqC0GUqYI6MrqHIYDHPFIgcxXAlbxpHT3tVwjyHBdo8kDQDLqGGmi3BHOEEXXN5UaSmqbYy_yW2Bp_Gswdsdh2j_pBt50WuHjFwMdiKspBnXCpXYuCmgkyKyJEhTzxXhBZ70YxuLGvIdWL-WMQ69c_DmJQhJmWIURks1mvFlwZr5F-CR6QqsTkq29qoeERpcUo8exZ7riXISuETpagPW2C_Ce-rI9nrSH4xaOebBA86gmiGZOf2YUdv2zfAmJVS_UOL7TeKHNd2sozbWW0xaO9Sy1T6l6tipUVwxcZA3mJ7Ruuvmkbf1nXcgcWCznxoBQg7vXsnn3_VGOqcE2hpgN-pmTlXndr4zR__t_tH7Baao_jd6fRsn93G_wxNneIB264uV-oJOq5VcqhtBLD4mm3Sbx9tsVY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oral+nutritional+supplements+containing+n-3+polyunsaturated+fatty+acids+affect+quality+of+life+and+functional+status+in+lung+cancer+patients+during+multimodality+treatment%3A+an+RCT&rft.jtitle=European+journal+of+clinical+nutrition&rft.au=van+der+Meij%2C+B.S&rft.au=Langius%2C+J.A.E&rft.au=Spreeuwenberg%2C+M.D&rft.au=Slootmaker%2C+S.M&rft.date=2012-03-01&rft.pub=Nature+Publishing+Group&rft.issn=0954-3007&rft.volume=66&rft.issue=3&rft.spage=399&rft_id=info:doi/10.1038%2Fejcn.2011.214&rft.externalDocID=A282938915
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0954-3007&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0954-3007&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0954-3007&client=summon